ORCHID PHARMA LIMITED
ORCHPHARMA · General/Diversified · NSE
₹707
Current Market Price
Under Review— We don’t have enough data to publish a fair value estimate for ORCHPHARMA yet. Reason: Data Limited.
Updated just now
YieldIQ Score
—
Piotroski F-Score
3/9
Economic Moat
None
Confidence
4%
ROE
7.9%
Debt/Equity
0.14
WACC
11.1%
Market Cap
₹3,583 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
10.0%
Return on capital employed
EV / EBITDA
—
Enterprise multiple
Debt / EBITDA
31.2×
Leverage vs earnings
Interest Coverage
7.6×
EBIT covers interest
Current Ratio
2.83×
Short-term liquidity
Asset Turnover
0.50×
Revenue per ₹ of assets
Revenue CAGR (3Y)
6.8%
3-year revenue growth
Revenue CAGR (5Y)
—
5-year revenue growth
Ratio Trends
ORCHPHARMA · last 5 annual periods
ROE
7.9%
ROCE
10.0%
Operating Margin
—
Debt / Equity
0.14×
PE
—
EV / EBITDA
27.5×
Historical Financials
ORCHPHARMA · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2022 NSE_XBRL | 2023 NSE_XBRL | 2024 NSE_XBRL | 2025 yfinance | 2026 yfinance | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹560 Cr | ₹666 Cr | ₹819 Cr | ₹922 Cr | ₹811 Cr | +9.7% |
| EBITDA | ₹62.1 Cr | ₹142 Cr | ₹142 Cr | ₹145 Cr | ₹69.7 Cr | +2.9% |
| EBIT | ₹-28.4 Cr | ₹87.5 Cr | ₹108 Cr | — | — | — |
| PAT | ₹-2.0 Cr | ₹46.3 Cr | ₹92.2 Cr | ₹99.7 Cr | ₹20.5 Cr | — |
| EPS (diluted) | ₹-0.48 | ₹13.01 | ₹19.06 | — | — | — |
| CFO | ₹92.5 Cr | ₹18.3 Cr | ₹126 Cr | ₹19.2 Cr | ₹101 Cr | +2.3% |
| CapEx | ₹-14.4 Cr | ₹-84.9 Cr | ₹-64.8 Cr | ₹-150 Cr | ₹-384 Cr | — |
| FCF | ₹78.1 Cr | ₹-66.6 Cr | ₹61.2 Cr | ₹-131 Cr | ₹-282 Cr | — |
| Total Assets | ₹1111 Cr | ₹1225 Cr | ₹1554 Cr | ₹1688 Cr | ₹1911 Cr | +14.5% |
| Total Debt | ₹268 Cr | ₹331 Cr | ₹135 Cr | ₹175 Cr | ₹363 Cr | +7.9% |
| Shareholders' Equity | ₹647 Cr | ₹689 Cr | ₹1169 Cr | ₹1267 Cr | ₹1288 Cr | +18.8% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
ORCHPHARMA vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
 GUFICBIO GUFICBIO | — | — | Pending | 11.6% | — |
BLISSGVS BLISSGVS | — | — | Pending | 10.8% | 17.7× |
 IOLCP IOLCP | — | — | Pending | 7.7% | 15.5× |
 RPGLIFE RPGLIFE | — | — | Pending | 34.5% | — |
 UNICHEMLAB UNICHEMLAB | — | — | Pending | 5.6% | — |
Click a ticker to view its fair-value analysis.
Dividend History
No dividend events recorded for ORCHPHARMA in the last 10 years.
Risk Analysis
Volatility & drawdown
Risk profile of ORCHPHARMA →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for ORCHPHARMA →
Compare
Head-to-head with peers
Compare ORCHPHARMA side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse ORCHPHARMANow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.